Valeant Pharmaceuticals International Stock Price, News & Analysis (TSE:VRX)

C$28.30 0.12 (0.43 %)
(As of 12/14/2017 09:56 AM ET)
Previous CloseC$28.18
Today's RangeC$26.83 - C$29.28
52-Week RangeC$11.20 - C$29.28
Volume6.07 million shs
Average Volume1.52 million shs
Market CapitalizationC$9.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.67

About Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorHealthcare
SymbolTSE:VRX
CUSIPN/A
Phone+1-514-7446792

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC$5.01
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%

Miscellaneous

EmployeesN/A
Outstanding Shares348,592,000

Valeant Pharmaceuticals International (TSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."

When will Valeant Pharmaceuticals International make its next earnings announcement?

Valeant Pharmaceuticals International is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Valeant Pharmaceuticals International.

Where is Valeant Pharmaceuticals International's stock going? Where will Valeant Pharmaceuticals International's stock price be in 2017?

5 equities research analysts have issued 1 year price targets for Valeant Pharmaceuticals International's stock. Their forecasts range from C$19.00 to C$25.50. On average, they expect Valeant Pharmaceuticals International's share price to reach C$22.50 in the next year. View Analyst Ratings for Valeant Pharmaceuticals International.

Who are some of Valeant Pharmaceuticals International's key competitors?

Who are Valeant Pharmaceuticals International's key executives?

Valeant Pharmaceuticals International's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer (Age 61)
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President (Age 61)
  • Christina Ackermann, Executive Vice President, General Counsel (Age 52)
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International (Age 55)
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology (Age 50)
  • Thomas W. Ross Sr, Lead Independent Director (Age 66)
  • Richard U. DeSchutter, Independent Director (Age 76)
  • Fredric N. Eshelman Ph.D., Independent Director (Age 68)
  • D. Robert Hale, Independent Director (Age 32)
  • Argeris N. Karabelas Ph.D., Independent Director (Age 64)

How do I buy Valeant Pharmaceuticals International stock?

Shares of Valeant Pharmaceuticals International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals International's stock price today?

One share of Valeant Pharmaceuticals International stock can currently be purchased for approximately C$28.30.

How big of a company is Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International has a market capitalization of C$9.21 billion.

How can I contact Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.


MarketBeat Community Rating for Valeant Pharmaceuticals International (VRX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  406
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeant Pharmaceuticals International (TSE:VRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.402.202.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$22.50C$22.50C$23.33C$21.83
Price Target Upside: 18.86% upside18.86% upside8.78% upside21.57% upside

Valeant Pharmaceuticals International (TSE:VRX) Consensus Price Target History

Price Target History for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE:VRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/8/2017Royal Bank of CanadaReiterated RatingSector PerformC$23.00View Rating Details
11/8/2017TD SecuritiesUpgradeHold -> BuyC$25.50View Rating Details
6/29/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Valeant Pharmaceuticals International (TSE:VRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE VRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
5/8/2014C$1.83C$1.90C$2.05 billionViewN/AView Earnings Details
8/7/20132Q13C$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Valeant Pharmaceuticals International (TSE:VRX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171$1.05$1.05$1.05
Q4 20171$1.01$1.01$1.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Valeant Pharmaceuticals International (TSE:VRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Valeant Pharmaceuticals International (TSE VRX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE VRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017Schutter Richard Urbain DeDirectorBuy10,000C$14.33C$143,300.00
8/21/2017Schutter Richard Urbain DeDirectorBuy4,900C$14.35C$70,315.00
8/9/2017John PaulsonDirectorSell24,700C$14.66C$362,102.00
5/11/2017Schutter Richard Urbain DeDirectorBuy20,000C$13.90C$278,000.00
3/15/2017Schutter Richard Urbain DeDirectorBuy10,000C$10.80C$108,000.00
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46
(Data available from 1/1/2013 forward)

Headlines

Valeant Pharmaceuticals International (TSE VRX) News Headlines

Source:
DateHeadline
CANADA STOCKS-TSX advances, lifted by Valeant, financial servicesCANADA STOCKS-TSX advances, lifted by Valeant, financial services
finance.yahoo.com - December 12 at 11:00 AM
Drug industry group sues to stop California drug price lawDrug industry group sues to stop California drug price law
finance.yahoo.com - December 9 at 10:31 AM
Vetr Upgrades Valeant After Price DipsVetr Upgrades Valeant After Price Dips
finance.yahoo.com - December 8 at 10:39 AM
Valeant: What Debt Problem? - Seeking AlphaValeant: What Debt Problem? - Seeking Alpha
seekingalpha.com - December 7 at 4:39 PM
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in NovemberThe Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
finance.yahoo.com - December 6 at 10:49 AM
Investing Guru Jim Simons Rolls Out the Red Carpet for Valeant Pharmaceuticals, Cuts Opko HealthInvesting Guru Jim Simons Rolls Out the Red Carpet for Valeant Pharmaceuticals, Cuts Opko Health
finance.yahoo.com - December 5 at 12:16 PM
Valeant Announces Launch Of Private Offering Of Senior NotesValeant Announces Launch Of Private Offering Of Senior Notes
finance.yahoo.com - December 4 at 10:33 AM
Valeant Pharma (VRX), Subsidiary Commence Cash Tender Offers For Up to $1B Outstanding Principal AmountValeant Pharma (VRX), Subsidiary Commence Cash Tender Offers For Up to $1B Outstanding Principal Amount
www.streetinsider.com - December 4 at 10:33 AM
Valeant Pharmaceuticals Intl Inc.: If You’d Bought the Dip, You’re upValeant Pharmaceuticals Intl Inc.: If You’d Bought the Dip, You’re up
www.fool.ca - November 30 at 11:13 AM
Quant Billionaire David Shaw Beats the Drum for Valeant Pharmaceuticals International, Inc. (VRX) and MannKind Corporation (MNKD)Quant Billionaire David Shaw Beats the Drum for Valeant Pharmaceuticals International, Inc. (VRX) and MannKind Corporation (MNKD)
finance.yahoo.com - November 27 at 3:36 PM
EYEG: Cataract Surgery Study Completes Enrollment, Topline Data Expected Q1 18EYEG: Cataract Surgery Study Completes Enrollment, Topline Data Expected Q1 18
finance.yahoo.com - November 27 at 3:36 PM
Valeant Pharmaceuticals International, Inc. (VRX) Given Consensus Recommendation of "Hold" by BrokeragesValeant Pharmaceuticals International, Inc. (VRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 24 at 3:56 AM
Valeant Pharma (VRX) Closes Add-On Secured Notes And Credit Agreement AmendmentValeant Pharma (VRX) Closes Add-On Secured Notes And Credit Agreement Amendment
www.streetinsider.com - November 22 at 5:42 PM
Insider Buying: Valeant Pharmaceuticals International, Inc. (VRX) Director Buys 10,000 Shares of StockInsider Buying: Valeant Pharmaceuticals International, Inc. (VRX) Director Buys 10,000 Shares of Stock
www.americanbankingnews.com - November 21 at 9:10 PM
Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling ProgramBausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
finance.yahoo.com - November 16 at 7:23 AM
Valeant Pharma (VRX) Launches Private Offering of Add-On Secured Notes - StreetInsider.comValeant Pharma (VRX) Launches Private Offering of Add-On Secured Notes - StreetInsider.com
www.streetinsider.com - November 13 at 11:13 AM
Valeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the AlarmValeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the Alarm
finance.yahoo.com - November 13 at 11:13 AM
Valeant Stock Tumbles on $750 Million Debt Offering AnnouncementValeant Stock Tumbles on $750 Million Debt Offering Announcement
finance.yahoo.com - November 13 at 11:13 AM
Edited Transcript of VRX.TO earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of VRX.TO earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 12 at 6:15 PM
Valeant Surges Post-Q3: A Reassessment - Seeking AlphaValeant Surges Post-Q3: A Reassessment - Seeking Alpha
seekingalpha.com - November 12 at 1:14 PM
Valeant Pharmaceuticals Intl Inc (VRX) Upgraded to Buy by TD SecuritiesValeant Pharmaceuticals Intl Inc (VRX) Upgraded to Buy by TD Securities
www.americanbankingnews.com - November 8 at 3:06 PM
Valeant Pharmaceuticals Intls (VRX) Sector Perform Rating Reiterated at Royal Bank Of CanadaValeant Pharmaceuticals Intl's (VRX) Sector Perform Rating Reiterated at Royal Bank Of Canada
www.americanbankingnews.com - November 8 at 3:06 PM
Valeant Pharmaceuticals Intl Inc.’s Q3 Results Boosted by Non-Operating ItemsValeant Pharmaceuticals Intl Inc.’s Q3 Results Boosted by Non-Operating Items
www.fool.ca - November 7 at 11:25 PM
[$$] Valeant plays down break-up but considers name change[$$] Valeant plays down break-up but considers name change
finance.yahoo.com - November 7 at 6:21 PM
Florida will sue pharmaceutical company over pension lossesFlorida will sue pharmaceutical company over pension losses
finance.yahoo.com - November 7 at 6:21 PM
US STOCKS-Wall Street recedes, Priceline and banks weighUS STOCKS-Wall Street recedes, Priceline and banks weigh
finance.yahoo.com - November 7 at 6:21 PM
Why Valeant Pharmaceuticals International, Denbury Resources, and Kindred Healthcare Jumped TodayWhy Valeant Pharmaceuticals International, Denbury Resources, and Kindred Healthcare Jumped Today
finance.yahoo.com - November 7 at 6:21 PM
US STOCKS-Dow edges up to record high, financials dipsUS STOCKS-Dow edges up to record high, financials dips
finance.yahoo.com - November 7 at 6:21 PM
CANADA STOCKS-TSX adds to record highs as Valeant shares surgeCANADA STOCKS-TSX adds to record highs as Valeant shares surge
finance.yahoo.com - November 7 at 6:21 PM
Valeant Pharmaceuticals Intl Inc. Has Thrown in the Towel: Should You?Valeant Pharmaceuticals Intl Inc. Has Thrown in the Towel: Should You?
www.msn.com - November 7 at 1:20 PM
Valeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but Theres a CatchValeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a Catch
www.fool.com - November 7 at 1:20 PM
Valeant Pharmaceuticals International (VRX) Q3 2017 Results - Earnings Call TranscriptValeant Pharmaceuticals International (VRX) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 1:20 PM
Valeant Earnings Soar on Tax BenefitValeant Earnings Soar on Tax Benefit
finance.yahoo.com - November 7 at 1:20 PM
Stocks to Watch: Apple, ADP, Priceline, Valeant, TripAdvisor, Salesforce, Hain CelestialStocks to Watch: Apple, ADP, Priceline, Valeant, TripAdvisor, Salesforce, Hain Celestial
finance.yahoo.com - November 7 at 1:20 PM
US STOCKS-Wall St hits new records as healthcare stocks riseUS STOCKS-Wall St hits new records as healthcare stocks rise
finance.yahoo.com - November 7 at 1:20 PM
Valeant Pharmaceuticals: Long-Time Bear Gives Kudos for “Smart” Addyi SaleValeant Pharmaceuticals: Long-Time Bear Gives Kudos for “Smart” Addyi Sale
finance.yahoo.com - November 7 at 1:20 PM
Valeant: So Youre Saying Its Good News?Valeant: So You're Saying It's Good News?
finance.yahoo.com - November 7 at 1:20 PM
CANADA STOCKS-TSX touches fresh record as Valeant jumps; resources slipCANADA STOCKS-TSX touches fresh record as Valeant jumps; resources slip
finance.yahoo.com - November 7 at 1:20 PM
Valeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a CatchValeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a Catch
finance.yahoo.com - November 7 at 1:20 PM
Valeants Explosive Gains Make the Stock Look Buyable AgainValeant's Explosive Gains Make the Stock Look Buyable Again
finance.yahoo.com - November 7 at 1:20 PM
Why Valeant Pharmaceuticals International Stock Is Shooting Higher TodayWhy Valeant Pharmaceuticals International Stock Is Shooting Higher Today
finance.yahoo.com - November 7 at 1:20 PM
Valeant to sell female libido pill business back to former ownersValeant to sell female libido pill business back to former owners
finance.yahoo.com - November 6 at 9:00 AM
[$$] Valeant to Divest Itself of Sprout Pharmaceuticals Unit[$$] Valeant to Divest Itself of Sprout Pharmaceuticals Unit
finance.yahoo.com - November 6 at 9:00 AM
Valeant Pharma (VRX) Confirms FDA Approval Of VYZULTAValeant Pharma (VRX) Confirms FDA Approval Of VYZULTA
www.streetinsider.com - November 2 at 8:57 PM
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%
finance.yahoo.com - November 2 at 8:57 PM
How Financially Strong Is Valeant Pharmaceuticals International Inc (VRX)?How Financially Strong Is Valeant Pharmaceuticals International Inc (VRX)?
finance.yahoo.com - November 2 at 8:57 PM
Valeant: Earnings, Debt Repayment, and What to Watch Next WeekValeant: Earnings, Debt Repayment, and What to Watch Next Week
finance.yahoo.com - November 2 at 11:07 AM
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis TreatmentOrtho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
finance.yahoo.com - November 2 at 11:07 AM
Valeant says its on track to pay down more than $5 bln in debt, ahead of goalValeant says it's on track to pay down more than $5 bln in debt, ahead of goal
finance.yahoo.com - October 31 at 11:56 AM
CANADA STOCKS-TSX touches fresh record, Shopify tumblesCANADA STOCKS-TSX touches fresh record, Shopify tumbles
finance.yahoo.com - October 31 at 11:56 AM

SEC Filings

Valeant Pharmaceuticals International (TSE:VRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Valeant Pharmaceuticals International (TSE VRX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.